Hot Stocks List: Today's Biggest Gainers

All three indexes are in the red this afternoon, but there are still hot stocks today soaring as much as 130%.

hot stocks today

Initial public offerings (IPOs) took center stage Friday, with five debuts. It would have been six if Globoforce hadn't postponed its IPO (citing unfavorable market conditions).

Yet plenty other stocks were also making news. Following are 12 of Friday's hot stocks to watch.

Today's Hot Stocks List

A10 Networks Inc. (NYSE: ATEN) shares rose 7% to a high of $16.50 intraday in its first day of trading. The San Jose, Calif. networking solutions company priced 12.5 million shares at $15. That was at the high end of the $13 to $15 range.

Amber Road Inc. (NYSE: AMBR), another new issue, soared 32% to a high of $17.90 intraday after it debuted. The East Rutherford, N.J. global trade management solution company priced 7,391,565 shares at $13, above the expected range of $10.50 to $12.

AVEO Pharmaceuticals Inc. (Nasdaq: AVEO) jumped 15% to $1.88 after regaining worldwide rights from Biogen Idec Inc. (Nasdaq: BIIB). The rights are in regard to AV-203, an antibody that reportedly has broad therapeutic potential for the treatment of cancer and other diseases. Last May, AV-203 successfully completed a phase 1 safety study that showed no dose-limiting toxicities across an entire dose range, up to and including the maximum dose of 20 mg/kg. Results from that study are expected to be presented this year. Biogen shares slipped 5%.

Borderfree Inc. (Nasdaq: BRDR) shares surged nearly 30% intraday to $21.25 in its first day trading as a public company. The NYC-headquartered cross-border solutions company priced 5 million shares at $16, the high end of the $14 to $16 expected range.

Endocyte Inc. (Nasdaq: ECYT) shares surged as much as 130% to a new 52-week high of $33.70 intraday. Gains followed reports that ECYT's experimental cancer drug, vintafolide, when used in tandem with chemotherapy, boosted survival rates in patients with non-recurrent lung cancer. That prompted RBC Capital Markets to suggest the company could become an attractive takeover target.

Lin Media LLC. (NYSE: LIN) shares jumped 25% intraday to $28.26 after Media General Inc. (NYSE: MEG) announced it will acquire LIN in a $2.6 billion cash, stock, and debt deal. The tie-up will create the nation's second-largest "pure-play" television broadcasting company. MEG shares rose some 7%.

Starbucks Corp. (Nasdaq: SBUX) shares were jolted nearly 1% higher to $78.64 after the company said it is looking to expand alcohol sales to "thousands of select stores" in the near future. Earlier in the week, SBUX announced the introduction of celebrity blends. First up is a select tea from Oprah Winfrey.

Tiffany & Co. (NYSE: TIF) sparkled after posting Q4 results. Sales rose 5% year over year and 2% for the quarter. Looking ahead, TIF anticipates earnings in the range of $4.05 to $4.15 per share, with worldwide sales increasing by a high single-digit percentage rate. The company plans to add 13 new stores this year and will close four underperforming locations.

TPG Specialty Lending Inc. (NYSE: TSLX) shares rose roughly 3% to $16.44 in its NYSE debut. The business development company of privately held TPG Capital raised about $112 million after its IPO of 7 million shares was priced at $16, the low end of the expected range. Since its 2011 launch, the BDC has raised some $1.5 billion from investors, including a $117.1 million commitment from its parent.

Unwired Planet Inc. (Nasdaq: UPIP) shares soared 60% to $2.20 intraday. By 1 p.m., nearly 10 million shares changed hands compared to the stock's average daily volume of 415,000. Sending shares sharply higher was news $11 billion market cap Lenovo Group (Nasdaq: LNGVY) is purchasing 21 patent families from $219 million market cap UPIP in a deal valued at $100 million.

Versartis Inc. (Nasdaq: VSAR) shares skyrocketed 70% to $36 after pricing 6 million shares at $21, the high end of the $19 to $21 expected range. Founded in 2008, the Redwood City, Calif. entity is a development-stage biopharmaceutical company. Its focus is on developing therapeutic proteins for the treatment of metabolic and endocrine disorders. Currently in phase 2 clinical trials is its VRS-317, a long-acting recombinant human growth hormone.

Visa Inc. (NYSE: V) shares rose 6% to $232.70 intraday on news a federal appeals court has upheld an earlier U.S. Federal Reserve ruling that capped debit card swipe fees at $0.21. The ruling is a win for credit and debit card companies, and a loss for retailers who challenged the ruling. Indeed, transaction fees cost retailers billions of dollars every year. In separate Visa news, the credit card giant has stopped providing payment services to Russia's bank Rossiya, following U.S. imposed sanctions on the country.

NOW: The Biggest "Buy" Signal We've Seen...